March 14th 2024
In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
Addressing Unmet Needs and Treatment Gaps in the Clinical Management of Neovascular Age-Related Macular Degeneration: Practical Strategies for Pharmacists in Specialty and Man...
1.5 Credits / Ophthalmology/Optometry
View More
Management of Neuromyelitis Optica Spectrum Disorder: Expert Insights and Updates for Pharmacists, featuring a Patient Perspective
1.5 Credits / Ophthalmology/Optometry
View More
The Promising Role of Novel Targeted Therapies in Addressing Clinical and Economic Burdens in Diabetic Macular Edema
1.5 Credits / Ophthalmology/Optometry
View More
Improving Outcomes and Quality of Care in Age-Related Macular Degeneration and Diabetic Macular Edema: Patient-Centered Strategies in Managed Care
3.0 Credits / Ophthalmology/Optometry
View More
Maximizing Patient Outcomes in Ophthalmologic Diseases: How Managed Care Professionals Play a Key Role in Facilitating Uptake of Biosimilars
1.0 Credit / Ophthalmology/Optometry
View More
Stakeholders Joust Over Biosimilar Availability at PCOC20
September 25th 2020A diverse panel from practice, payer, and wholesale perspectives convened at The American Journal of Managed Care®'s Patient-Centered Oncology Care® 2020 virtual conference to hash out one of the hottest issues in biosimilar availability right now.
Vizient Looks to Biosimilars To Temper COVID-19 Price Inflation
July 31st 2020Vizient predicts that drug price inflation, partly due to the coronavirus disease 2019 (COVID-19), will be 3.29% in 2021 and is banking on biosimilars to help contain the rising cost of medication, it said in a comprehensive review for its member health companies.
Interview: Medicines for Europe Reports on EU Biosimilar Success
July 27th 2020The Center for Biosimilars® (CfB) spoke with Adrian van den Hoven, director general of Medicines for Europe, and Diogo Piedade, market access manager for Medicines for Europe, about their scorecard report for biosimilar access in European markets.
Polpharma Biologics Moves Forward With Bioceros Integration
July 16th 2020Polpharma Biologics said it is close to finishing its integration of Bioceros, a company it acquired 4 years ago. The acquisition gave Polpharma an advanced cell line development platform, and with a bioreactor facility nearing completion, the company said it is poised for growth.
Meta-Analysis Finds No Increased Mortality for Patients Treated With Intravitreal Anti-VEGFs
December 30th 2019Intravitreal injection with anti–vascular endothelial growth factor (anti-VEGF) drugs has represented a major step forward for patients with retinal diseases, and the upcoming biosimilars market for these drugs—including aflibercept and ranibizumab, as well as off-label bevacizumab—is beginning to take shape. However, there have been some lingering concerns about the safety of these drugs, as increased mortality has been reported after anti-VEGF treatment in the general population.
Switching to Anti-TNF Biosimilars Is a Feasible Treatment Choice in Uveitis, Study Finds
December 12th 2019Given the availability of biosimilars of infliximab, etanercept, and adalimumab in multiple markets worldwide, and given the cost savings associated with the biosimilars, there is growing interest in switching patients receiving maintenance treatment for uveitis to these biosimilar options, but data in switching patients with uveitis have been limited.
Anti-VEGFs May Provide Substantial Economic Value to Patients and Society in Treating Wet AMD
November 18th 2019The field of biosimilar contenders for anti–vascular endothelial growth factor (anti-VEGF) therapies is taking shape, with biosimilar developer Coherus seeking to launch its ranibizumab biosimilar in 2021 and Samsung Bioepis having reached a commercialization agreement for 2 biosimilar anti-VEGFs of its own. Last week, a study published in JAMA Ophthalmology supported the use of anti-VEGF agents in wet age-related macular degeneration (AMD), saying that, though these drugs are costly, they may provide substantial economic value to both patients and society.
New Anti-VEGF Agent, Brolucizumab, Cleared by FDA to Treat AMD
October 8th 2019Even as biosimilars of anti–vascular endothelial growth factor (anti-VEGF) agents are coming to market and advancing through the pipeline, a new agent that may have substantial benefits for patients with wet age-related macular degeneration (AMD) has been approved by the FDA: brolucizumab, which sponsor Novartis will sell as Beovu.
Vial Sharing for Bevacizumab in Treating Eye Disorders Reduces Costs, Increases Access
September 18th 2019Vial sharing for bevacizumab that would otherwise have been discarded yielded a 97.88% reduction in the total cost of a single year of intravitreal injections, as well as a 96.54% increase in the number of injections performed.
Eye on Pharma: FDA Gives Green Light to Aflibercept in Prefilled Syringe
August 14th 2019Regeneron’s aflibercept (Eylea) has been approved by the FDA for a prefilled syringe (PFS) presentation. The 2-mg, single-dose, PFS will offer the greater ease of use less preparation than the vial presentation of the drug used to treat a range of eye disorders.
Ahead of Biosimilar Competition, Ranibizumab Gets a Positive CHMP Opinion for New Indication
July 28th 2019Novartis, developer of the brand-name Lucentis, announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has granted the drug a positive opinion for the treatment of retinopathy of prematurity in infants.